Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant

University of Manitoba

$817,320.00

ATM and TDP1 coordinate neurodevelopment and modulate Top1-mediated anti-cancer therapeutic outcome

EF 2013-14

Résumé
It is estimated that the individual lifetime risk of developing cancer is 1-in-3 and death is 1-in-5. These grim statistics are a sobering reminder of the critical need to develop more effective ways to cure cancer. Patients afflicted with malignant glioma, a devastating brain tumour, have an abysmal prognosis with death usually occurring within 14 months of diagnosis. Despite highly invasive surgical, radiation and chemotherapeutic strategies, malignant glioma is considered an incurable disease. The targeted use of compounds that modulate DNA repair enzymes to affect tumour cell killing is an emerging tool in cancer chemotherapeutics. Studies have shown that the brain is especially susceptible to dysregulation of the DNA damage repair response, however; the biology of the associated DNA repair pathways and the function of the key enzymes remain poorly understood. I will identify mechanisms that selectively modulate cellular DNA repair activity in brain tumours to increase the efficacy of frontline radio- and chemotherapeutic drugs. My research findings will improve current cancer treatment strategies, patient survival and quality-of-life.
Programme
Operating Grant
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
305959
Name
Katyal Sachin
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
ATM and TDP1 coordinate neurodevelopment and modulate Top1-mediated anti-cancer therapeutic outcome
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$817,320
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Brain Tumours; Cancer Genetics; Chemoradiotherapy; Chemotherapy; Malignant Glioma; Mouse Models; Neurodegenerative Disease; Novel Therapeutics; Radiotherapy; Topoisomerase
Abstract
It is estimated that the individual lifetime risk of developing cancer is 1-in-3 and death is 1-in-5. These grim statistics are a sobering reminder of the critical need to develop more effective ways to cure cancer. Patients afflicted with malignant glioma, a devastating brain tumour, have an abysmal prognosis with death usually occurring within 14 months of diagnosis. Despite highly invasive surgical, radiation and chemotherapeutic strategies, malignant glioma is considered an incurable disease. The targeted use of compounds that modulate DNA repair enzymes to affect tumour cell killing is an emerging tool in cancer chemotherapeutics. Studies have shown that the brain is especially susceptible to dysregulation of the DNA damage repair response, however; the biology of the associated DNA repair pathways and the function of the key enzymes remain poorly understood. I will identify mechanisms that selectively modulate cellular DNA repair activity in brain tumours to increase the efficacy of frontline radio- and chemotherapeutic drugs. My research findings will improve current cancer treatment strategies, patient survival and quality-of-life.
Competitiondate
201403
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Katyal, Sachin
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $817,320~ $0~